Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.

Publication ,  Journal Article
Buckner, CD; Fefer, A; Bensinger, WI; Storb, R; Durie, BG; Appelbaum, FR; Petersen, FB; Weiden, P; Clift, RA; Sanders, JE
Published in: Eur J Haematol Suppl
1989

28 patients with plasma cell malignancies received marrow transplants from identical twins (N = 8), HLA-identical family members (N = 15), HLA partially-matched relatives (N = 3) or cryopreserved autologous marrow (N = 2). Treatment regimens included cyclophosphamide (CY) and total body irradiation (TBI) for 15 patients and busulphan (BU) and CY for 13 patients. 3 of 8 twins are alive, 2 without disease at 24 and 34 months, and 1 is alive and well at 116 months without evidence of disease except for at small residual monoclonal protein spike. 12 of the 18 allografted patients died of transplant-related causes and 2 died of progressive disease. 4 of 18 allograft recipients are alive; 2 are free of disease at 16 and 15 months, 1 is alive at 6 months without disease except for persistent monoclonal Kappa protein. 1 patient is alive with residual marrow involvement and a persistent IGA lambda monoclonal protein at 7 months. 1 of the 2 autograft recipients is alive 2 months after transplant and is not yet evaluable for tumor response and the other patient died early of transplant-related complications. Both CY + TBI and BU + CY resulted in remissions in patients with advanced plasma cell malignancies. However, the optimal treatment regimen and timing of transplantation remain to be determined.

Duke Scholars

Published In

Eur J Haematol Suppl

DOI

ISSN

0902-4506

Publication Date

1989

Volume

51

Start / End Page

186 / 190

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Leukemia, Plasma Cell
  • Humans
  • Evaluation Studies as Topic
  • Diseases in Twins
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Buckner, C. D., Fefer, A., Bensinger, W. I., Storb, R., Durie, B. G., Appelbaum, F. R., … Sanders, J. E. (1989). Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl, 51, 186–190. https://doi.org/10.1111/j.1600-0609.1989.tb01515.x
Buckner, C. D., A. Fefer, W. I. Bensinger, R. Storb, B. G. Durie, F. R. Appelbaum, F. B. Petersen, P. Weiden, R. A. Clift, and J. E. Sanders. “Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.Eur J Haematol Suppl 51 (1989): 186–90. https://doi.org/10.1111/j.1600-0609.1989.tb01515.x.
Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl. 1989;51:186–90.
Buckner, C. D., et al. “Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience.Eur J Haematol Suppl, vol. 51, 1989, pp. 186–90. Pubmed, doi:10.1111/j.1600-0609.1989.tb01515.x.
Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR, Petersen FB, Weiden P, Clift RA, Sanders JE. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl. 1989;51:186–190.

Published In

Eur J Haematol Suppl

DOI

ISSN

0902-4506

Publication Date

1989

Volume

51

Start / End Page

186 / 190

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Transplantation, Homologous
  • Transplantation, Autologous
  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Leukemia, Plasma Cell
  • Humans
  • Evaluation Studies as Topic
  • Diseases in Twins
  • Combined Modality Therapy